²é¿´: 1130  |  »Ø¸´: 4
µ±Ç°Ö÷ÌâÒѾ­´æµµ¡£

kitty-II

Í­³æ (СÓÐÃûÆø)

[½»Á÷] ¼±ÇóÀûÓÃÊɾúÌåչʾ¼¼Êõɸѡ¿¹Ìå·½ÃæµÄ×ÊÁÏ

×î½ü¸Õ¸Õ¿ªÊ¼¹¹½¨¿¹ÌåÎĿ⣬ÀûÓÃÊɾúÌåչʾ¼¼Êõɸѡ¿¹ÌåµÄʵÑ飬µ«ÓÉÓÚÍêȫûÕâ·½ÃæµÄ»ù´¡ÖªÊ¶£¬²»ÖªµÀ´ÓºÎÏÂÊÖ¡£¸÷λºÃÐĵÄXDJMÃÇ£¬Èç¹ûÄÜÌṩÕâ·½ÃæµÄµç×Ó×ÊÁÏ£¨ Ïà¹ØµÄÂÛÎĺ͵ç×ÓÊé½Ô¿É£¬×îºÃÊÇÖÐÎĵģ©£¬±¾È˽«²»Éõ¸Ð¼¤£¬Ç뽫µç×Ó×ÊÁÏ·¢ËÍÖÁ liyu50864306@yahoo.cn
»Ø¸´´ËÂ¥
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

qingfengwu

½ð³æ (СÓÐÃûÆø)

ÊɾúÌåչʾ¼¼ÊõµÄÔ­Àí¼°Ó¦ÓÃ

¡ï
kitty-II(½ð±Ò+1,VIP+0): 12-1 15:50
Ç׺Íɸѡ¿ÉÓÃÖ±½Ó·¨ºÍ¼ä½Ó·¨. Ö±½Ó·¨Êǽ«µ°°×ÖÊ·Ö×ÓñîÁªµ½¹ÌÏàÖ§³ÖÎïÉÏ£¬ÎÄ¿âÊɾúÌåÓë¹ÌÏàÖ§³ÖÎïÎÂÓý£¬Ï´È¥Î´½áºÏµÄÊɾúÌ壬¼È»ñµÃÇ׺ÍÊɾúÌ壻¼ä½Ó·¨Êǽ«ÉúÎïËØ±ê¼ÇµÄµ°°×ÖÊ·Ö×ÓÓëÎÄ¿âÊɾúÌåÎÂÓýºóÆÌÔÚ½áºÏÓÐÁ´Ç׺ÍËØµÄƽÃóÉÏ£¬Ï´È¥Î´½áºÏµÄÊɾúÌ壬±£ÁôµÄ¾ÍÊǽáºÏ״̬µÄÊɾúÌ壬ÔÙÏ´ÍѽáºÏµÄÊɾúÌ壬ÓÃÕⲿ·ÖÊɾúÌå¸ÐȾϸ¾ú£¬À©ÔöÊɾúÌ壬¿ªÊ¼ÐÂÒ»ÂÖµÄɸѡ£¬Í¨¹ý¼¸´ÎÕâÑùµÄÇ׺ʹ¿»¯·´Ó¦£¬¾ÍÄÜÑ¡ÔñÐԵظ»¼¯²¢ÌØÒìÐÔÀ©Ôö½áºÏÕâÖÖµ°°×ÖÊ»òDNA ·Ö×ÓµÄÊɾúÌå. ɸѡ³öµÄÊɾúÌåµÄ½áºÏÌØÐÔ¿ÉÒÔ½øÒ»²½ÑéÖ¤²¢´ÓDNA ÐòÁÐÍÆµ¼³öÀ´£¬·ÖÎö¸÷¸ö¿Ë¡¼ä±àÂë¶ÌëĵÄÒ»ÖÂÐòÁУ¬ÒÔȷ֤ɸѡµÄÌØÒìÐÔ. ×îºó£¬ÀûÓû¯Ñ§ºÏ³Éº¬Ò»ÖÂÐòÁеݱ»ùËá¶ÌëÄ£¬Ñо¿ËûÃǵÄÇ׺ÍÌØÐÔ²¢ÍƲâ¿ÉÄÜÅäÌåµÄÉúÎïѧ»îÐԺͽáºÏ»òÓÎÀë״̬µÄ½á¹¹Ìصã.
Ç׺Íɸѡ¿ÉÓÃÖ±½Ó·¨ºÍ¼ä½Ó·¨. Ö±½Ó·¨Êǽ«µ°°×ÖÊ·Ö×ÓñîÁªµ½¹ÌÏàÖ§³ÖÎïÉÏ£¬ÎÄ¿âÊɾúÌåÓë¹ÌÏàÖ§³ÖÎïÎÂÓý£¬Ï´È¥Î´½áºÏµÄÊɾúÌ壬¼È»ñµÃÇ׺ÍÊɾúÌ壻¼ä½Ó·¨Êǽ«ÉúÎïËØ±ê¼ÇµÄµ°°×ÖÊ·Ö×ÓÓëÎÄ¿âÊɾúÌåÎÂÓýºóÆÌÔÚ½áºÏÓÐÁ´Ç׺ÍËØµÄƽÃóÉÏ£¬Ï´È¥Î´½áºÏµÄÊɾúÌ壬±£ÁôµÄ¾ÍÊǽáºÏ״̬µÄÊɾúÌ壬ÔÙÏ´ÍѽáºÏµÄÊɾúÌ壬ÓÃÕⲿ·ÖÊɾúÌå¸ÐȾϸ¾ú£¬À©ÔöÊɾúÌ壬¿ªÊ¼ÐÂÒ»ÂÖµÄɸѡ£¬Í¨¹ý¼¸´ÎÕâÑùµÄÇ׺ʹ¿»¯·´Ó¦£¬¾ÍÄÜÑ¡ÔñÐԵظ»¼¯²¢ÌØÒìÐÔÀ©Ôö½áºÏÕâÖÖµ°°×ÖÊ»òDNA ·Ö×ÓµÄÊɾúÌå. ɸѡ³öµÄÊɾúÌåµÄ½áºÏÌØÐÔ¿ÉÒÔ½øÒ»²½ÑéÖ¤²¢´ÓDNA ÐòÁÐÍÆµ¼³öÀ´£¬·ÖÎö¸÷¸ö¿Ë¡¼ä±àÂë¶ÌëĵÄÒ»ÖÂÐòÁУ¬ÒÔȷ֤ɸѡµÄÌØÒìÐÔ. ×îºó£¬ÀûÓû¯Ñ§ºÏ³Éº¬Ò»ÖÂÐòÁеݱ»ùËá¶ÌëÄ£¬Ñо¿ËûÃǵÄÇ׺ÍÌØÐÔ²¢ÍƲâ¿ÉÄÜÅäÌåµÄÉúÎïѧ»îÐԺͽáºÏ»òÓÎÀë״̬µÄ½á¹¹Ìصã.
2Â¥2009-12-01 14:39:21
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

qingfengwu

½ð³æ (СÓÐÃûÆø)

¡ï ¡ï
kitty-II(½ð±Ò+2,VIP+0): 12-1 15:50
3 ÊɾúÌåչʾ¼¼ÊõµÄÓ¦ÓÃ

3.1 ÊɾúÌåËæ»ú¶àëÄÎÄ¿â ëÄ¿âÊǸÐȾÐÔÊɾúÌåµÄ¼¯ºÏ£¬ÆäÖÐÿ¸ö²¡¶¾Á£×ÓµÄÒ¿DZíÃæ¶¼º¬ÓÐÒÔÈںϵ°°×ÐÎʽÏÔ¶µÄΨһµÄºËÜÕËá˳Ðò±àÂë¹ÑëÄ£¬Í¨¹ýÑ¡Ôñ²½Öè¿ÉÒÔ¸»¼¯Óë°Ð·Ö×Ó½áºÏµÄÊɾúÌå. ¹¹½¨Ëæ»ú¶àëÄÎÄ¿âÒ»°ãÏÈÌåÍâºÏ³É±àÂë¶ÌëĵÄËæ»úDNA Ƭ¶Î£¬¾­PCR À©Ôö»òÔÓ½»Ê¹ÆäÐγÉЯ´øÊʵ±Ã¸ÇÐλµãµÄ»ùÒòƬ¶Î£¬»ò¾­PCR À©ÔöÄ³ÌØ¶¨»ùÒòºóÔÙÓÃDNase ¢ñø½â£¬Ê¹ÆäÐγɳ¤¶Ì²»Ò»µÄС»ùÒòƬ¶Î. Ëæ»úëÄ¿âµÄÓ¦Ó÷¶Î§ÒÀ²ÉÓõÄɸѡ·Ö×Ó¶øÑÔ£¬ÕâЩɸѡ·Ö×Ó°üÀ¨¿¹Ì塢С·Ö×Ó¡¢Ï¸°û±íÃæÊÜÌåÀࡢϸ°û·Ö×ÓÀà¡¢ÍêÕûϸ°ûµÈ£¬ÕâЩ·Ö×Ó³ÆÎªÊÜÌåÀà. ɸѡ³öµÄ½áºÏ¸ÃÀàÊÜÌåµÄÄ¿µÄ·Ö×Ó³ÆÎªÅäÌå. Óô¿»¯µÄµ¥¿Ë¡¿¹Ìå×÷ÊÜÌ壬½øÐп¹ÌåµÄ±íλ·ÖÎöÓ¦ÓÃ×î¹ã·ºÒ²×î³ÉÊ죬ɸѡ³öµÄÅäÌåͨ³£±íÃ÷ÁË¿¹Ô­¿¹ÌåµÄ½áºÏ²¿Î». Blond-Elguindi et al [4]²ÉÓü×Ì¥µ°°× (AFP)Ï´ÍѵIJßÂÔɸѡ³öBip½áºÏ¶ÌëĵĹ²ÓÐÐòÁУ¬²ûÃ÷ Bipʶ±ðºÍµ°°×ÖÊÕÛµþµÄ»úÖÆ. ÓÃϸ°û±íÃæµÄÌìÈ»ÊÜÌå×÷ɸѡ·Ö×ÓÊÇɸѡ¼¼ÊõµÄÒ»´ó½ø²½£¬Doorbar et al [5]²ÉÓþºÕùÏ´Íѵķ½·¨É¸Ñ¡³öϸ°û±íÃæÊÜÌåÌØÒìÐÔ½áºÏµÄ¶ÌëÄ£¬Pasqualini et al [6]³É¹¦µØÉ¸Ñ¡³ö³¦ºÍθ×éÖ¯ÌØÒìÐԵĶÌëÄ£¬Ô¤Ê¾ÓпÉÄÜÓÃÓÚÌåÄÚ»ùÒòµÄ¶¨Ïò×ªÒÆ. ÊɾúÌåչʾ¼¼ÊõÒ²¿ÉÒÔÓÃÓÚ²¡¶¾µÄÕï¶Ï¡¢ÖÎÁƺÍÒßÃçµÄ·¢Õ¹£¬ Folgori et al [7]ÒÔÒÒÐ͸ÎÑײ¡¶¾±íÃæ¿¹Ô­(HbsAg)ΪģÐÍ, ÓÃÒÒÐ͸ÎÑ×»¼ÕßÌØÒìÐÔѪÇåɸѡëĿ⣬ÓÃÃâÒßÓ¡¼£¼ø¶¨ÊɾúÌå±íλ,ÓÃÕý³£ÈËѪÇå·´Ïòɸѡ,×îÖյõ½µÄ¶ÌëÄ¿ÉÄ£ÄâHBsAg ²¢ÓɾºÕù½áºÏÊÔÑéÑéÖ¤. Motti et al [8]ÔÚ¶Ô HBV µÄÑо¿ÖУ¬Óÿ¹²¡¶¾µ¥¿Ë¡¿¹Ìåɸѡ³öÄ£Äâ±íλ, ÃâÒߺó¿ÉÒýÆð»úÌåÌØÒìÐԵĶÔHBsAg µÄ»úÌåÃâÒߣ¬ÌáʾģÄâ¶ÌëÄ¿ÉÓÃÓÚÒßÃçµÄ·¢Õ¹. Arnon et al [9]ÓðËëÄËæ»úëÄ¿âɸѡÂüÊÏѪÎü³æµÄÄ£Äâ±í룬ÈÏΪģÄâ±íλ¿ÉÒÔ×÷Ϊ¶àëÄÒßÃçµÄÖØÒª³É·Ö. ÀûÓÃëĿ⼼ÊõÈ·¶¨ÁËɳÑÛÒÂÔ­ÌåÖ÷ÒªÍâ¿Çµ°°×µÄ±íλ[10]¡¢HCV ºËÐÄ¿¹Ô­±íλ[11]¡¢HIV gp 120 µ°°×ºÍHCV ºËÐĵ°°×µÄ±íλ[12]. ÀûÓÃÊɾúÌåëĿ⼼ÊõÒѾ­È·¶¨ÁËÐí¶àµ°°×·Ö×ÓµÄÏ໥×÷ÓÃλµã£¬°üÀ¨×é³ÉµÄSH3 ÓëÀÒ°±Ëáµ°°×¼¤Ã¸µÄ½áºÏλµã[13]¡¢°ûÖʵ°°× p47phox Óëϸ°ûÉ«ËØb558 µÄ½áºÏλµã[14]. ÓÃÇ׺ʹ¿»¯µÄ HLA-DR13´ÓÊɾúÌåëÄ¿âÖеö³öÓëÖ®½áºÏµÄ¶àëÄ£¬Í¨¹ý MHCÓë¶àëĵĽáºÏ»ùÐò·ÖÎöMHC-I·Ö×ӵĽáºÏÌØµã[15]. Wrighton et al [16]ɸѡµ½¾ßÓдٺìϸ°ûÉú³ÉËØ(EPO)¹¦ÄÜ»îÐÔµÄÓɶþ¼üÁ¬½ÓµÄ»·ÐζÌëÄ. ËûÓÃÖØ×é¿ÉÈÜÐÔºìϸ°ûÉú³ÉËØÊÜÌå(EPO-R)ÏÈɸѡÓëgp120 Èںϱí´ïµÄ¹¹ÏóÔ¼ÊøÐÍÊɾúÌå°ËëĿ⣬µÃµ½ÓëEPO-R ÌØÒìÐÔ½áºÏ£¬ÇÒ²»ÓëţѪÇå°×µ°°×(BSA)¡¢Ö×Áö»µËÀÒò×ÓÊÜÌå(TNFR)µÄ°ûÍâÇø¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌå(NGF-R)¡¢°×½éËØ-2 ÊÜÌå (IL-2R)µÄ¦Á ºÍ¦Â ÑÇ»ùÒÔ¼°E Ñ¡ÔñËØ½áºÏµÄ»·ëÄ[16]. 3.2 ÊɾúÌ忹Ìå¿â ÊɾúÌ忹Ìå¿â¼¼ÊõÀûÓÃ˿״ÊɾúÌåÔØÌå¹¹½¨¿¹ÌåÎĿ⣬ͨ¹ýÒÑÖª¿¹Ô­É¸Ñ¡ÌØÒìÐÔ¸ßÇ׺ÍÐÔ¿¹ÌåµÄ¼¼Êõ. McCaffery et al [3]Ê×ÏÈÖ¤Ã÷£¬ÍêÕûµÄ¿¹Ìå¿É±äÇø¿É±í´ïÓÚÊɾúÌåµÄ±íÃæ£¬Í¨¹ýÇ׺Íɸѡ»ñµÃÁËÓëÒÑÖª¿¹Ô­ÌØÒìÐÔ½áºÏµÄµ¥Á´¿¹Ì寬¶Î£¬Hogrefe et al [17] ÓÖ´Ó¹¹½¨µÄFab ÎÄ¿âɸѡµ½ÌØÒìµÄFab Ƭ¶Î.

ÿÖÖ¿¹ÌåµÄ¿É±äÇøÓɳ¬±äÇøºÍ¹Ç¼ÜÇø(FR)×é³É£¬³¬±äÇøÓֳƻ¥²¹¾ö¶¨Çø(CDR)¾ö¶¨¿¹Ô­µÄ½áºÏλµã£¬Æä°±»ùËáÐòÁбäÒì½Ï´ó£¬¶øÁ¬½Ó³¬±äÇøµÄ¹Ç¼ÜÇøºÜ±£ÊØ. ÊɾúÌ忹Ìå¿âÔËÓÃÁËÈýÏîʵÑé¼¼Êõ£º(1)Äæ×ªÂ¼¶à¾ÛøÁ´·´Ó¦(RT-PCR)¼¼Êõ£¬ÓÃÒ»ÖÖÒýÎï¿Ë¡³öÈ«Ì×ÃâÒßÇòµ°°×¿É±äÇø»ùÒò£»(2)²ÉÓô󳦸˾ú·ÖÃÚ±í´ï¾ßÓÐÉúÎï»îÐԵĿ¹Ì幦ÄÜÆ¬¶Î£»(3)ÊɾúÌå±íÃæÕ¹Ê¾¼¼ÊõµÄ½¨Á¢£¬ÆäÖ÷Òª¼¼ÊõÁ÷³ÌÊÇ£¬´ÓÃâÒß»ò²»¾­ÃâÒßµÄÈ˺ÍСÊóµÄÆ¢ÁܰÍϸ°ûÖÐÌáÈ¡mRNA£¬·´×ªÂ¼³ÉcDNA£¬Ê¹ÓÃÓ뿹Ìå¿É±äÇø»ùÒòÁ½²à±£ÊØÇø»¥²¹µÄÒýÎͨ¹ý¶à¾ÛøÁ´·´Ó¦(PCR)·Ö±ðÀ©Ôö¿¹Ìå¿É±äÇøµÄÖØÁ´(VH)ºÍÇáÁ´(VL) »ùÒò£¬¹¹½¨ÎÄ¿â. ²åÈëÊɾúÌåÔØÌåºóÓжþÖÖ±í´ïģʽ£¬¼´±í´ïscFv µ¥Á´¿¹Ìå»òFab ¿¹Ì壬scFv ÓÉVH ºÍVL Ö®¼äͨ¹ýÈ˹¤½ÓÍ·ÏàÁ¬£»¶øFab Ƭ¶ÎµÄVH+CH1ºÍVL+CL ·Ö±ð²åÈ벻ͬµÄÊɾúÌåÔØÌå,¶þÖÖÖØ×éÊɾúÌ峬¸ÐȾͬһËÞÖ÷¾ú,VL+CL ¾Í¿ÉÓëVH+CH1 Ƭ¶Îͨ¹ý¶þÁò¼ü½áºÏÐγÉFab Ƭ¶Î. ½«ÊɾúÌ忹ÌåÎÄ¿âͨ¹ýÌØÒìÐÔ¿¹Ô­µÄɸѡ,¾Í¿ÉÒԵõ½º¬ÌØÒìÐÔ¿¹Ì寬¶ÎµÄÊɾúÌå.
ÊɾúÌ忹Ìå¿â¼¼ÊõÄ£ÄâÁË»úÌåÃâÒßϵͳµÄÑ¡Ôñ×÷Ó㬳ÊÏÖÔÚÊɾúÌå±íÃæµÄ¿¹ÌåÄܹ»ÔÚÌåÍâÓùÌÏ໯¿¹Ô­½øÐÐɸѡ£¬Í¬Ê±ÓÉÓÚÊɾúÌå¶Ô´ó³¦¸Ë¾úµÄ¸ÐȾÐÔ£¬ÊɾúÌ忹Ìå¿â¼¼ÊõÄܹ»ÒÔÌÔɸµÄ·½Ê½£¬Îª¿ìËÙÑ¡ÔñÌØÒìÐÔ¿¹ÌåÌṩ¼ò±ã¶ø¸ßЧµÄ²Ù×÷ϵͳ£¬¾ßÌåµÄ²½Ö裺(1)ÊɾúÌå𤸽°Ð¿¹Ô­.(2)·´¸´Ï´µÓÈ¥³ý·ÇÌØÒìÐÔ½áºÏ£¬Ï´ÍѲ¢ÊÕ¼¯Ó뿹ԭ½áºÏµÄÊɾúÌå. (3)ÔٴθÐȾ´ó³¦¸Ë¾ú£¬Ê¹ÌØÒìµÄÊɾúÌ忹ÌåÌÔɸ. ³ý´ËÖ®Í⣬ҲÓÐÓùÌÏàÌÔɸ¡¢²¶»ñÌÔÑ¡¡¢ÍêÕûϸ°ûÌÔɸ¡¢×éÖ¯ÌÔɸ¼°Æ÷¹ÙÌÔɸµÈ·½·¨»ñµÃ½áºÏ¿¹Ìå³É¹¦µÄ±¨µÀ£¬µ«¸÷ÓвàÖØ£¬ÎªÊɾúÌ忹ÌåµÄÌÔɸÔöÌíеÄ;¾¶[18]. Clackson et al [19]Ê×ÏȰÑËûÓõ½scFv µÄ±í´ïÖÐÀ´. ËûʹÓûùÒò¹¤³Ì¸ÄÔìÊɾúÌåÔØÌ壬ÔÙÔÚ¸¨ÖúÕß(Helper)ÊɾúÌåµÄ°ïÖúÏ£¬½á¹ûʹscFv ÔÚÊɾúÌåµÄÒ¿ǵ°°×G3P µÄ¶¥²¿±í´ï. ÕâÖÖscFv ÒѾßÓнáºÏ»îÐÔ£¬Òò´ËÄܷܺ½±ãµØ´ÓÒ»¸ö¿âÖÐɸѡ³öÐèÒªµÄscFv ÊɾúÁ£ (phagemid)À´. 1996 Ä꣬Tang et al [20]ÓÃÊɾúÌåչʾ¼¼ÊõµÄ·½·¨£¬¶ÔÒ»¸öÁ¬½ÓëÄ¿â×÷ÁËɸѡ£¬½á¹ûµÃµ½ºÜ¶à½áºÏÄÜÁ¦½ÏÇ¿µÄscFv µÄÁ¬½ÓëÄ¡£

3.3 µ°°×Öʵ͍Ïò¸ÄÔì µ°°×Öʵ͍Ïò¸ÄÔìÖ¸µÄÊÇÓúÐʽͻ±ä¡¢´íÎóÇãÏòPCR µÈ·½·¨À´Í»±äµ°°×ÖÊ»ò½á¹¹ÓòµÄÄ³Ò»ÌØ¶¨±àÂëÐòÁУ¬²úÉúµ°°×ÖÊ»ò½á¹¹ÓòµÄÍ»±äÎÄ¿â³ÊÏÖÔÚÊɾúÌå±íÃæ£¬Í¨¹ýÇ׺Íɸѡ»ñµÃËùÐèµÄÒѶ¨Ïò¸Ä±äµÄÊɾúÌå¿Ë¡£¬ËûÃǵÄÒ»¼¶½á¹¹¿ÉÒÔ´ÓDNA µÄÐòÁÐÖÐÍÆµ¼³öÀ´. ¿ÉÓÃÀ´É¸Ñ¡¾ßÓиüÇ¿ÊÜÌå½áºÏÄÜÁ¦µÄϸ°ûÒò×Ó¡¢ÐµÄøÒÖÖÆ¼Á¡¢×ªÂ¼Òò×ÓµÄDNA ½áºÏÐÂλµã¡¢ÐµÄϸ°ûÒò×ÓÞ׿¹¼Á¡¢ÐÂÐÍøºÍÔöÇ¿ÉúÎïѧ»îÐԵĵ°°×ÖʵÈ.



3 ÊɾúÌåչʾ¼¼ÊõµÄÓ¦ÓÃ

3.1 ÊɾúÌåËæ»ú¶àëÄÎÄ¿â ëÄ¿âÊǸÐȾÐÔÊɾúÌåµÄ¼¯ºÏ£¬ÆäÖÐÿ¸ö²¡¶¾Á£×ÓµÄÒ¿DZíÃæ¶¼º¬ÓÐÒÔÈںϵ°°×ÐÎʽÏÔ¶µÄΨһµÄºËÜÕËá˳Ðò±àÂë¹ÑëÄ£¬Í¨¹ýÑ¡Ôñ²½Öè¿ÉÒÔ¸»¼¯Óë°Ð·Ö×Ó½áºÏµÄÊɾúÌå. ¹¹½¨Ëæ»ú¶àëÄÎÄ¿âÒ»°ãÏÈÌåÍâºÏ³É±àÂë¶ÌëĵÄËæ»úDNA Ƭ¶Î£¬¾­PCR À©Ôö»òÔÓ½»Ê¹ÆäÐγÉЯ´øÊʵ±Ã¸ÇÐλµãµÄ»ùÒòƬ¶Î£¬»ò¾­PCR À©ÔöÄ³ÌØ¶¨»ùÒòºóÔÙÓÃDNase ¢ñø½â£¬Ê¹ÆäÐγɳ¤¶Ì²»Ò»µÄС»ùÒòƬ¶Î. Ëæ»úëÄ¿âµÄÓ¦Ó÷¶Î§ÒÀ²ÉÓõÄɸѡ·Ö×Ó¶øÑÔ£¬ÕâЩɸѡ·Ö×Ó°üÀ¨¿¹Ì塢С·Ö×Ó¡¢Ï¸°û±íÃæÊÜÌåÀࡢϸ°û·Ö×ÓÀà¡¢ÍêÕûϸ°ûµÈ£¬ÕâЩ·Ö×Ó³ÆÎªÊÜÌåÀà. ɸѡ³öµÄ½áºÏ¸ÃÀàÊÜÌåµÄÄ¿µÄ·Ö×Ó³ÆÎªÅäÌå. Óô¿»¯µÄµ¥¿Ë¡¿¹Ìå×÷ÊÜÌ壬½øÐп¹ÌåµÄ±íλ·ÖÎöÓ¦ÓÃ×î¹ã·ºÒ²×î³ÉÊ죬ɸѡ³öµÄÅäÌåͨ³£±íÃ÷ÁË¿¹Ô­¿¹ÌåµÄ½áºÏ²¿Î». Blond-Elguindi et al [4]²ÉÓü×Ì¥µ°°× (AFP)Ï´ÍѵIJßÂÔɸѡ³öBip½áºÏ¶ÌëĵĹ²ÓÐÐòÁУ¬²ûÃ÷ Bipʶ±ðºÍµ°°×ÖÊÕÛµþµÄ»úÖÆ. ÓÃϸ°û±íÃæµÄÌìÈ»ÊÜÌå×÷ɸѡ·Ö×ÓÊÇɸѡ¼¼ÊõµÄÒ»´ó½ø²½£¬Doorbar et al [5]²ÉÓþºÕùÏ´Íѵķ½·¨É¸Ñ¡³öϸ°û±íÃæÊÜÌåÌØÒìÐÔ½áºÏµÄ¶ÌëÄ£¬Pasqualini et al [6]³É¹¦µØÉ¸Ñ¡³ö³¦ºÍθ×éÖ¯ÌØÒìÐԵĶÌëÄ£¬Ô¤Ê¾ÓпÉÄÜÓÃÓÚÌåÄÚ»ùÒòµÄ¶¨Ïò×ªÒÆ. ÊɾúÌåչʾ¼¼ÊõÒ²¿ÉÒÔÓÃÓÚ²¡¶¾µÄÕï¶Ï¡¢ÖÎÁƺÍÒßÃçµÄ·¢Õ¹£¬ Folgori et al [7]ÒÔÒÒÐ͸ÎÑײ¡¶¾±íÃæ¿¹Ô­(HbsAg)ΪģÐÍ, ÓÃÒÒÐ͸ÎÑ×»¼ÕßÌØÒìÐÔѪÇåɸѡëĿ⣬ÓÃÃâÒßÓ¡¼£¼ø¶¨ÊɾúÌå±íλ,ÓÃÕý³£ÈËѪÇå·´Ïòɸѡ,×îÖյõ½µÄ¶ÌëÄ¿ÉÄ£ÄâHBsAg ²¢ÓɾºÕù½áºÏÊÔÑéÑéÖ¤. Motti et al [8]ÔÚ¶Ô HBV µÄÑо¿ÖУ¬Óÿ¹²¡¶¾µ¥¿Ë¡¿¹Ìåɸѡ³öÄ£Äâ±íλ, ÃâÒߺó¿ÉÒýÆð»úÌåÌØÒìÐԵĶÔHBsAg µÄ»úÌåÃâÒߣ¬ÌáʾģÄâ¶ÌëÄ¿ÉÓÃÓÚÒßÃçµÄ·¢Õ¹. Arnon et al [9]ÓðËëÄËæ»úëÄ¿âɸѡÂüÊÏѪÎü³æµÄÄ£Äâ±í룬ÈÏΪģÄâ±íλ¿ÉÒÔ×÷Ϊ¶àëÄÒßÃçµÄÖØÒª³É·Ö. ÀûÓÃëĿ⼼ÊõÈ·¶¨ÁËɳÑÛÒÂÔ­ÌåÖ÷ÒªÍâ¿Çµ°°×µÄ±íλ[10]¡¢HCV ºËÐÄ¿¹Ô­±íλ[11]¡¢HIV gp 120 µ°°×ºÍHCV ºËÐĵ°°×µÄ±íλ[12]. ÀûÓÃÊɾúÌåëĿ⼼ÊõÒѾ­È·¶¨ÁËÐí¶àµ°°×·Ö×ÓµÄÏ໥×÷ÓÃλµã£¬°üÀ¨×é³ÉµÄSH3 ÓëÀÒ°±Ëáµ°°×¼¤Ã¸µÄ½áºÏλµã[13]¡¢°ûÖʵ°°× p47phox Óëϸ°ûÉ«ËØb558 µÄ½áºÏλµã[14]. ÓÃÇ׺ʹ¿»¯µÄ HLA-DR13´ÓÊɾúÌåëÄ¿âÖеö³öÓëÖ®½áºÏµÄ¶àëÄ£¬Í¨¹ý MHCÓë¶àëĵĽáºÏ»ùÐò·ÖÎöMHC-I·Ö×ӵĽáºÏÌØµã[15]. Wrighton et al [16]ɸѡµ½¾ßÓдٺìϸ°ûÉú³ÉËØ(EPO)¹¦ÄÜ»îÐÔµÄÓɶþ¼üÁ¬½ÓµÄ»·ÐζÌëÄ. ËûÓÃÖØ×é¿ÉÈÜÐÔºìϸ°ûÉú³ÉËØÊÜÌå(EPO-R)ÏÈɸѡÓëgp120 Èںϱí´ïµÄ¹¹ÏóÔ¼ÊøÐÍÊɾúÌå°ËëĿ⣬µÃµ½ÓëEPO-R ÌØÒìÐÔ½áºÏ£¬ÇÒ²»ÓëţѪÇå°×µ°°×(BSA)¡¢Ö×Áö»µËÀÒò×ÓÊÜÌå(TNFR)µÄ°ûÍâÇø¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌå(NGF-R)¡¢°×½éËØ-2 ÊÜÌå (IL-2R)µÄ¦Á ºÍ¦Â ÑÇ»ùÒÔ¼°E Ñ¡ÔñËØ½áºÏµÄ»·ëÄ[16]. 3.2 ÊɾúÌ忹Ìå¿â ÊɾúÌ忹Ìå¿â¼¼ÊõÀûÓÃ˿״ÊɾúÌåÔØÌå¹¹½¨¿¹ÌåÎĿ⣬ͨ¹ýÒÑÖª¿¹Ô­É¸Ñ¡ÌØÒìÐÔ¸ßÇ׺ÍÐÔ¿¹ÌåµÄ¼¼Êõ. McCaffery et al [3]Ê×ÏÈÖ¤Ã÷£¬ÍêÕûµÄ¿¹Ìå¿É±äÇø¿É±í´ïÓÚÊɾúÌåµÄ±íÃæ£¬Í¨¹ýÇ׺Íɸѡ»ñµÃÁËÓëÒÑÖª¿¹Ô­ÌØÒìÐÔ½áºÏµÄµ¥Á´¿¹Ì寬¶Î£¬Hogrefe et al [17] ÓÖ´Ó¹¹½¨µÄFab ÎÄ¿âɸѡµ½ÌØÒìµÄFab Ƭ¶Î.

ÿÖÖ¿¹ÌåµÄ¿É±äÇøÓɳ¬±äÇøºÍ¹Ç¼ÜÇø(FR)×é³É£¬³¬±äÇøÓֳƻ¥²¹¾ö¶¨Çø(CDR)¾ö¶¨¿¹Ô­µÄ½áºÏλµã£¬Æä°±»ùËáÐòÁбäÒì½Ï´ó£¬¶øÁ¬½Ó³¬±äÇøµÄ¹Ç¼ÜÇøºÜ±£ÊØ. ÊɾúÌ忹Ìå¿âÔËÓÃÁËÈýÏîʵÑé¼¼Êõ£º(1)Äæ×ªÂ¼¶à¾ÛøÁ´·´Ó¦(RT-PCR)¼¼Êõ£¬ÓÃÒ»ÖÖÒýÎï¿Ë¡³öÈ«Ì×ÃâÒßÇòµ°°×¿É±äÇø»ùÒò£»(2)²ÉÓô󳦸˾ú·ÖÃÚ±í´ï¾ßÓÐÉúÎï»îÐԵĿ¹Ì幦ÄÜÆ¬¶Î£»(3)ÊɾúÌå±íÃæÕ¹Ê¾¼¼ÊõµÄ½¨Á¢£¬ÆäÖ÷Òª¼¼ÊõÁ÷³ÌÊÇ£¬´ÓÃâÒß»ò²»¾­ÃâÒßµÄÈ˺ÍСÊóµÄÆ¢ÁܰÍϸ°ûÖÐÌáÈ¡mRNA£¬·´×ªÂ¼³ÉcDNA£¬Ê¹ÓÃÓ뿹Ìå¿É±äÇø»ùÒòÁ½²à±£ÊØÇø»¥²¹µÄÒýÎͨ¹ý¶à¾ÛøÁ´·´Ó¦(PCR)·Ö±ðÀ©Ôö¿¹Ìå¿É±äÇøµÄÖØÁ´(VH)ºÍÇáÁ´(VL) »ùÒò£¬¹¹½¨ÎÄ¿â. ²åÈëÊɾúÌåÔØÌåºóÓжþÖÖ±í´ïģʽ£¬¼´±í´ïscFv µ¥Á´¿¹Ìå»òFab ¿¹Ì壬scFv ÓÉVH ºÍVL Ö®¼äͨ¹ýÈ˹¤½ÓÍ·ÏàÁ¬£»¶øFab Ƭ¶ÎµÄVH+CH1ºÍVL+CL ·Ö±ð²åÈ벻ͬµÄÊɾúÌåÔØÌå,¶þÖÖÖØ×éÊɾúÌ峬¸ÐȾͬһËÞÖ÷¾ú,VL+CL ¾Í¿ÉÓëVH+CH1 Ƭ¶Îͨ¹ý¶þÁò¼ü½áºÏÐγÉFab Ƭ¶Î. ½«ÊɾúÌ忹ÌåÎÄ¿âͨ¹ýÌØÒìÐÔ¿¹Ô­µÄɸѡ,¾Í¿ÉÒԵõ½º¬ÌØÒìÐÔ¿¹Ì寬¶ÎµÄÊɾúÌå.
ÊɾúÌ忹Ìå¿â¼¼ÊõÄ£ÄâÁË»úÌåÃâÒßϵͳµÄÑ¡Ôñ×÷Ó㬳ÊÏÖÔÚÊɾúÌå±íÃæµÄ¿¹ÌåÄܹ»ÔÚÌåÍâÓùÌÏ໯¿¹Ô­½øÐÐɸѡ£¬Í¬Ê±ÓÉÓÚÊɾúÌå¶Ô´ó³¦¸Ë¾úµÄ¸ÐȾÐÔ£¬ÊɾúÌ忹Ìå¿â¼¼ÊõÄܹ»ÒÔÌÔɸµÄ·½Ê½£¬Îª¿ìËÙÑ¡ÔñÌØÒìÐÔ¿¹ÌåÌṩ¼ò±ã¶ø¸ßЧµÄ²Ù×÷ϵͳ£¬¾ßÌåµÄ²½Ö裺(1)ÊɾúÌå𤸽°Ð¿¹Ô­.(2)·´¸´Ï´µÓÈ¥³ý·ÇÌØÒìÐÔ½áºÏ£¬Ï´ÍѲ¢ÊÕ¼¯Ó뿹ԭ½áºÏµÄÊɾúÌå. (3)ÔٴθÐȾ´ó³¦¸Ë¾ú£¬Ê¹ÌØÒìµÄÊɾúÌ忹ÌåÌÔɸ. ³ý´ËÖ®Í⣬ҲÓÐÓùÌÏàÌÔɸ¡¢²¶»ñÌÔÑ¡¡¢ÍêÕûϸ°ûÌÔɸ¡¢×éÖ¯ÌÔɸ¼°Æ÷¹ÙÌÔɸµÈ·½·¨»ñµÃ½áºÏ¿¹Ìå³É¹¦µÄ±¨µÀ£¬µ«¸÷ÓвàÖØ£¬ÎªÊɾúÌ忹ÌåµÄÌÔɸÔöÌíеÄ;¾¶[18]. Clackson et al [19]Ê×ÏȰÑËûÓõ½scFv µÄ±í´ïÖÐÀ´. ËûʹÓûùÒò¹¤³Ì¸ÄÔìÊɾúÌåÔØÌ壬ÔÙÔÚ¸¨ÖúÕß(Helper)ÊɾúÌåµÄ°ïÖúÏ£¬½á¹ûʹscFv ÔÚÊɾúÌåµÄÒ¿ǵ°°×G3P µÄ¶¥²¿±í´ï. ÕâÖÖscFv ÒѾßÓнáºÏ»îÐÔ£¬Òò´ËÄܷܺ½±ãµØ´ÓÒ»¸ö¿âÖÐɸѡ³öÐèÒªµÄscFv ÊɾúÁ£ (phagemid)À´. 1996 Ä꣬Tang et al [20]ÓÃÊɾúÌåչʾ¼¼ÊõµÄ·½·¨£¬¶ÔÒ»¸öÁ¬½ÓëÄ¿â×÷ÁËɸѡ£¬½á¹ûµÃµ½ºÜ¶à½áºÏÄÜÁ¦½ÏÇ¿µÄscFv µÄÁ¬½ÓëÄ¡£

3.3 µ°°×Öʵ͍Ïò¸ÄÔì µ°°×Öʵ͍Ïò¸ÄÔìÖ¸µÄÊÇÓúÐʽͻ±ä¡¢´íÎóÇãÏòPCR µÈ·½·¨À´Í»±äµ°°×ÖÊ»ò½á¹¹ÓòµÄÄ³Ò»ÌØ¶¨±àÂëÐòÁУ¬²úÉúµ°°×ÖÊ»ò½á¹¹ÓòµÄÍ»±äÎÄ¿â³ÊÏÖÔÚÊɾúÌå±íÃæ£¬Í¨¹ýÇ׺Íɸѡ»ñµÃËùÐèµÄÒѶ¨Ïò¸Ä±äµÄÊɾúÌå¿Ë¡£¬ËûÃǵÄÒ»¼¶½á¹¹¿ÉÒÔ´ÓDNA µÄÐòÁÐÖÐÍÆµ¼³öÀ´. ¿ÉÓÃÀ´É¸Ñ¡¾ßÓиüÇ¿ÊÜÌå½áºÏÄÜÁ¦µÄϸ°ûÒò×Ó¡¢ÐµÄøÒÖÖÆ¼Á¡¢×ªÂ¼Òò×ÓµÄDNA ½áºÏÐÂλµã¡¢ÐµÄϸ°ûÒò×ÓÞ׿¹¼Á¡¢ÐÂÐÍøºÍÔöÇ¿ÉúÎïѧ»îÐԵĵ°°×ÖʵÈ.

3.4 cDNA ÎÄ¿âµÄ±í´ïɸѡ cDNA ÎÄ¿âµÄ±í´ïɸѡϵͳ³ýÀûÓæËÊɾúÌå¡¢½Íĸ˫ÔÓ½»ÏµÍ³Í⣬ÊɾúÌå±íÃæÕ¹Ê¾¼¼ÊõÒ²¿É´ïµ½Í¬ÑùµÄÄ¿µÄ[21-23]. cDNA±àÂëµÄËùÓе°°×ÖÊÈÚºÏÔÚfos ½á¹¹ÓòC Ä©¶Ë£¬ÓëJun-g ¢ó»òJun-g ¢ø½á¹¹ÓòÏ໥×÷Óã»Ò²¿É½«cDNA Ö±½ÓÈÚºÏÔÚp ¢óµÄC Ä©¶Ë£»ÁíÍâÊÇÖ±½ÓÀûÓõ°°×ÖÊÖ®¼äµÄÏ໥×÷ÓÃÀ´Ñ¡Ôñ cDNA£¬½«Ä¿µÄµ°°×ºÍcDNA ÎÄ¿â·Ö±ðÓëg ¢óµÄC Ä©¶ËºÍN¶ËÈںϣ¬Èç¹ûÄ¿µÄµ°°×Óëijһ¸öcDNA µÄµ°°×Ï໥×÷Óã¬g ¢óµ°°×µÄ¶þ¸ö¹¦ÄÜÓò½«±Ë´Ë»¥²¹µ¼ÖÂÓиÐȾÐԵIJ¡¶¾²úÉú. ÊɾúÌåչʾ¼¼ÊõÒý³öÁË·Ö×ÓÎÄ¿âµÄ¸ÅÄ¸ù¾ÝÎÄ¿â³ÊÏֵIJ¿Î»²»Í¬£¬ÓÐÊɾúÌå±íÃæÕ¹Ê¾ÎĿ⡢ϸ¾ú±íÃæÕ¹Ê¾ÎĿ⡢ÖÊÁ£Õ¹Ê¾ÎÄ¿âºÍºËÌÇÌåÎĿ⣬Ҳ¿ÉÒÔÊÇÓû¯Ñ§·½·¨ºÏ³ÉµÄëÄ¿â»òС·Ö×Ó»¯ºÏÎï¿â. ÆäÖÐÊɾúÌå±íÃæÕ¹Ê¾¼¼Êõ±È½Ï³ÉÊ죬¸ù¾ÝÎÄ¿âÄÚ·Ö×ÓµÄÐÔÖÊ¿ÉÒÔ·ÖΪcDNA ÎÄ¿â¡¢Ëæ»úëĿ⡢¿¹ÌåÎĿ⡢µ°°×ÖÊÎÄ¿âµÈ. ĿǰÒÑÔ½À´Ô½¹ã·ºµØÓÃÓÚ¿¹Ô­±íλ·ÖÎö¡¢µ°°×ÖÊ£­µ°°×ÖÊÏ໥×÷ÓÃλµã·ÖÎö¡¢Ã¸×÷Óõ×ÎïµÄ·ÖÎö¡¢Ñ°ÕÒ¾ßÓÐÉúÎ﹦Äܵĵ°°×µÄÄ£ÄâëÄ¡¢Ïȵ¼»¯ºÏÎïµÄ·¢ÏÖ¡¢·ÖÀëÓë¼ø¶¨¼²²¡ÌØÒìÐÔ¿¹Ô­Ä£ÄâëÄ¡¢É¸Ñ¡Ï¸°ûºÍÆ÷¹ÙÌØÒìÐÔ½áºÏëÄ¡¢Ñо¿µ°°×ÖÊÓëºËËá½áºÏÌØÐÔ¡¢¶¨Î»ÐźÅתµ¼Í¾¾¶µÈ. ¸Ã¼¼ÊõѸËÙ·¢Õ¹µÄÔ­ÒòÊÇËûÓÐЧµØÊµÏÖÁË»ùÒòÐͺͱíÐ͵Äת»»£¬ÔÚ·Ö×Ó¿Ë¡µÄ»ù´¡ÉÏ£¬ÊµÏÖµ°°×Öʹ¹ÏëµÄÌåÍâ¿ØÖÆ£¬´Ó¶ø¿É»ñµÃ¾ßÓÐÉúÎïѧ»îÐԵıí´ï²úÎï. Èô½«µ°°×ÖÊÈýά½á¹¹Ô¤²â¡¢·Ö×ÓÄ£Äâ¼¼Êõ¼°ÊɾúÌå±íÃæÕ¹Ê¾¼¼ÊõÍêÃÀÈںϣ¬¶Ô·Ö×ÓÏ໥×÷ÓᢷÖ×Óʶ±ð¡¢ÊÜÌå×÷Óá¢Ã¸Ñ§»úÖÆÒÔ¼°ÒßÃçµÄÑо¿½ø³Ì½«Æð¼«´óµÄÍÆ¶¯×÷ÓÃ.
4 ²Î¿¼ÎÄÏ×

1 Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985; 228:1315-1317 2 Parmley SF,Smith GP. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene 1988;73:305-318 3 McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990;348:552-554 4 Blond-Elguindi S, Cwirla SE, Dower WJ, Lipshutz RJ,Sprang SR, Sambrook JF, Gething MJ. Affinity panning of a library of peptides displayed on bacteriophages reveals the binding specificity of BiP. Cell 1993;75:717-728 5 Doorbar J, Winter G. Isolation of a peptide antagonist to the thrombin receptor using phage display. J Mol Biol 1994;244:361- 369 6 Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996;380:364-366 7 Folgori A, Tafi R, Meola A, Felici F, Gafre G, Cortese R, Monaci P, Nicosia A. A general strategy to identify mimotopes of pathological antigens using only random peptide libraries and human sera. EMBO J 1994;13:2236-2243 8 Motti C, Nuzzo M, Meola A, Galfre G, Felic F, Cortese R, Nicosia A, Monaci P. Recognition by human sera and immunogenicity of HBsAg mimotopes selected from an M13 phage display library. Gene 1994; 146:191-198 9 Arnon R, Tarrab-Hazdai R, Steward M. A mimotope peptidebased vaccine against Schistosomamansoni: synthesis and immunology. Immunology 2000;101:555-562 10 Zhong G, Smith GP, Berry J,Brunham RC. Conformational mimicry of a chlamydial neutralization epitope on filamentous phage. J Biol Chem 1994;269:24183-24188 11 Rodriguez-Lopez M, Riezu-Boj JI, Ruiz M,Berasain C, Civeira MP, Prieto J, Borras-Cuesta F. Immunogenicity of variable regions of hepatitis C virus proteins:selection and modification of peptide epitopes to assess hepatitis C virus genotypes by ELISA. J Gen Virol 1999;80:727-738 12 Grihalde ND, Cheny CJ, Golden A, Gubbins E, Mandecki W. Epitope mapping of anti-HIV and anti-HCV monoclonal antibodies and characterization of epitope mimics using a filamentous phage peptide library. Gene 1995;166:187-195 13 Sparks AB, Quilliam LA, Thorn JM, Der CJ, Kay BK. Identification Identification and characterization of Src SH3 ligands from phage-displayed random peptide libraries. J Biol Chem 1994;269:23853-23856 14 Deleo FR, Yu L, Burritt JB, Loetterle LR, Bond CW, Jesaitis AJ, Quinn MT.Mapping sites of interaction of p47-phox and flavocytochrome b with random-sequence peptide phage display libraries.Proc Natl Acad Sci USA 1995;92:7110-7114 15 Davenport MP, Quinn CL, Valsasnint P, Sinigaglia F, Hill AV, Bell JI. Analysis of peptide-binding motifs for two disease associated HLA-DR13 alleles using an M13 phage display library. Immunology 1996; 88:482-486 16 Wrighton NC, Farrell FX, Chang R, Rashyap AK, Barbone FP, Mulcahy LS, Johnson OL, Barrett RW, Jolliffe LK, Dower WJ. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996; 273:458-464 17 Hogrefe HH, Mullinax RL, Lovejoy AE, Hay BN, Sorge JA. A bacteriophage lambda vector for the cloning and expression of immunoglobulin Fab fragments on the surface of filamentous phage. Gene 1993;128:119-126 18 Breitling F, Dubel S, Seehaus T, Klewinghaus I, Little M.A surface expression vector for antibody screening. Gene 1991;104:147- 153 19 Clackson T, Hoogenboom HR, Griffiths AD, Winter G. Making antibody fragments using phage display libraries. Nature 1991; 352:624-628 20 Tang Y, Jiang N, Parakh C, Hilvert D. Selection of linkers for a catalytic single chain antibody using phage display technology. J Biol Chem 1996;271:15682-15686 21 Rhyner C, Kodzius R, Crameri R. Direct selection of cDNAs from filamentous phage surface display libraries: potential and limitations. Curr Pharm 2002;3:13-21 22 Crameri R, Walter G. Selective enrichment and high-throughput screening of phage surface-displayed cDNA libraries from complex allergenic systems. Comb Chem High Throug Screen 1999;2: 63-72 23 Crameri R, Kodzius R. The powerful combination of phage surface display of cDNA libraries and high throughput screening. Comb Chem High Throughput Screen 2001; 4:145-155
3Â¥2009-12-01 14:39:40
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

qingfengwu

½ð³æ (СÓÐÃûÆø)

ѧÊõÆÚ¿¯ > Öлª¼ìÑéҽѧÔÓÖ¾ > 2008Äê4ÆÚ > Ó¦ÓÃÊɾúÌåչʾ¼¼ÊõɸѡѪÐÍA¿¹Ô­±íλµÄÄ£Äâ¶àëÄ

    ÂÛÎÄÍø  
Ó¦ÓÃÊɾúÌåËæ»úëÄ¿âչʾ¼¼Êõɸѡ¸Î°©¿¹ÌåÄ£Äâëﰏ߻îÐÔÖØ×éµ°°×µÄ¹¹½¨

--------------------------------------------------------------------------------


ÂÛÎıêÌâ:Ó¦ÓÃÊɾúÌåËæ»úëÄ¿âչʾ¼¼Êõɸѡ¸Î°©¿¹ÌåÄ£Äâëﰏ߻îÐÔÖØ×éµ°°×µÄ¹¹½¨
Screening the Specific Mimic Peptide with Higher Affinity to SMMC-7721 and Constructing of Recombination Protein
ÂÛÎÄ×÷Õß Àƽ
ÂÛÎĵ¼Ê¦ ÐÜÕýÓ¢£»½ªÓÀÇ¿,ÂÛÎÄѧλ ˶ʿ,ÂÛÎÄרҵ Ô˶¯ÈËÌå¿ÆÑ§
ÂÛÎĵ¥Î» ÉÂÎ÷ʦ·¶´óѧ,µã»÷´ÎÊý 10,ÂÛÎÄÒ³Êý 53Ò³File Size3183k


Íò·½ÆÚ¿¯·ÖÀà > Ò½Ò©ÎÀÉú > Ò½Ò©ÎÀÉú×ÜÂÛ > ÆÚ¿¯ : ¸´µ©Ñ§±¨£¨Ò½Ñ§°æ£© ÊɾúÌåչʾ¼¼ÊõɸѡDNA´íÅäÐÞ¸´µ°°×MutS¸ßÇ׺ÍÐÔ¿¹Ìå

ÆÚ¿¯ : ϸ°ûÓë·Ö×ÓÃâÒßѧÔÓÖ¾ Ó¦ÓÃÊɾúÌåչʾ¼¼Êõɸѡ¡¢¼ø¶¨¿¹ººÌ²²¡¶¾µ¥¿Ë¡¿¹ÌåµÄÄ£Äâ±íλ
4Â¥2009-12-01 14:46:30
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

qingfengwu

½ð³æ (СÓÐÃûÆø)

¡ï ¡ï
kitty-II(½ð±Ò+2,VIP+0): 12-1 15:50
0 ÒýÑÔ

1985 ÄêSmith [1]Ê×´Î֤ʵ˿״ÊɾúÌåfd »ùÒò×éÄÜͨ¹ý»ùÒò¹¤³ÌµÄÊֶνøÐиÄÔ죬½«EcoR ¢ñÄÚÇÐøµÄ²¿·Ö»ùÒòƬ¶Î(171 bp ºÍ132 bp)Óëp ¢ó»ùÒòÈںϣ¬»ñµÃµÄÖØ×éÊɾúÌå¿ÉÔÚÌåÍâÎȶ¨ÔöÉú£¬±í´ï²úÎïÄܱ»¿¹EcoR ¢ñÄÚÇÐø¿¹ÌåËùʶ±ð. 1988 ÄêParmley et al [2]½«ÒÑÖª¿¹Ô­¾ö¶¨×åÓëp ¢óµÄN¶ËÈںϳÊÏÖÔÚ±íÃæ£¬¿ÉÌØÒìÐԵر»¿¹ÌåÑ¡Ôñ³öÀ´£¬²¢Ìá³öͨ¹ý¹¹½¨Ëæ»úëÄ¿â¿ÉÒÔÁ˽⿹Ìåʶ±ðµÄ¿¹Ô­¾ö¶¨´Ø±íλµÄÉèÏë. 1990 ÄêMcCafferty et al [3]Ò²±¨µÀÁËÓÃÊɾúÌåչʾ¼¼ÊõɸѡÈܾúøµÄµ¥Á´¿¹ÌåµÄ·½·¨£¬´Ó¶ø¿ªÊ¼ÁËÕâÏî¼¼ÊõµÄ¹ã·ºÓ¦ÓõÄÐÂʱ´ú.

1 ÊɾúÌåµÄ»ù±¾ÌØÕ÷

ÊɾúÌåÊôÓÚµ¥Á´DNA ²¡¶¾£¬°üÀ¨f1¡¢fd ºÍM13 ÈýÀà. ÊɾúÌåDNAÔÚϸ¾úÄÚ¹ö»·¸´ÖÆ,ϸ¾ú²»±»Áѽâ,µ«Éú³¤ËٶȼõÂý,¶øÇÒ¿É·ÖÃÚ³ö´óÁ¿³ÉÊìµÄÊɾúÌå¿ÅÁ£. ÊɾúÌåµÄµ¥Á´DNA ³¤Ô¼7 000 bp,²»Í¬ÀàÐÍÊɾúÌåÆäÒ»¼¶½á¹¹¼«ÎªÏàËÆ£¬»ùÒò×é±àÂë11 ÖÖµ°°×ÖÊ£¬ÆäÖÐ5 ÖÖΪ½á¹¹µ°°×£¬ÓëÊɾúÌåչʾÃÜÇÐÏà¹ØµÄÊǶþÖÖ²»Í¬µÄ½á¹¹µ°°×p ¢óºÍp¢ø. ÊɾúÌåµ¥Á´DNA±»°ü¹üÔÚ´óÔ¼2 700-3 000¸öÖ÷ÒªÒ¿ǵ°°×p ¢ø·Ö×Ó×é³ÉµÄ¹Ü×´½á¹¹ÖУ¬ÁíÍâ´ÎÒªÒ¿ǵ°°×p ¢óͨ¹ýÓë´ó³¦¸Ë¾úµÄF ¾úë½áºÏ¶øÒýÆð¸ÐȾ£¬ÊÇÊɾúÌå¸ÐȾËÞÖ÷Ëù±ØÐèµÄ. p ¢øÇ°ÌåÓÉ73 ¸ö°±»ùËá²Ð»ù×é³É£¬ÆäÖÐÐźÅëÄΪ23 ¸ö°±»ùËá²Ð»ù£¬¸ù¾Ý¹¹³ÉÍâ¿ÇµÄ¹¦ÄܿɷÖΪËĸöÇø£¬6-24 °±»ùËá²Ð»ùÇøÓòÕ¼¾ÝÊɾúÌå±íÃæµÄ´ó²¿·Ö£¬25-35 °±»ùËá²Ð»ùÇøÓò¸ß¶ÈÊèË®ÐÔ,C ¶Ë(35-50 °±»ùËá²Ð»ùÇøÓò)ÓëDNAÏà½áºÏ£¬¹¹³ÉÍêÕûµÄÄÚ±Ú£¬N¶Ë(1-5°±»ùËá²Ð»ùÇøÓò)Ϊ¿É»î¶¯µÄ¡¢Íâ¶ÔÚÊɾúÌå±íÃæµÄëĶΣ¬ÊDzåÈëÍâÔ´»ùÒòµÄ×î¼ÑλÖÃ. p¢óǰÌåÓÉ424 ¸ö°±»ùËá²Ð»ù×é³É£¬ÐγÉ3-5 ¸ö¿½±´£¬Î»ÓÚÊɾúÌåµÄβ²¿£¬ËûÓÉËĸö¹¦ÄÜÇø×é³É£¬ÐźÅëÄÇø(18 ¸ö°±»ùËá²Ð»ù)Òýµ¼p¢óÖÁϸ¾ú°û¼äÖÊ£¬ÔÚp¢ó·ÖÃÚºó±»Ï¸¾úµ°°×øˮ½â£¬ÆäºóµÄ´©Ä¤ÇøÓëÊɾúÌåµÄÇÖÈëÓйأ¬ÊÜÌå½áºÏÇø¸ºÔð½áºÏF ¾ú룬¶øC ¶ËµÄÊèË®Çø×éװǰ𤸽ÔÚϸ¾úÄÚĤÉÏ£¬×é×°ºóÕâ¶Î°±»ùËáÐòÁÐêÔÚÊɾúÌåÍâ¿ÇÉÏ£¬´©Ä¤ÇøÊÇ×îÍâ¶µÄÇøÓò£¬Òò¶ø³ÉΪ²åÈëÍâÔ´»ùÒòµÄÀíÏëλÖÃ.

2 ÊɾúÌåչʾ¼¼ÊõµÄ»ù±¾Ô­Àí

ÊɾúÌåչʾ¼¼ÊõÊÇÒ»ÖÖ»ùÒò±í´ï²úÎïºÍÇ׺ÍÑ¡ÔñÏà½áºÏµÄ¼¼Êõ£¬ËûÒԸĹ¹µÄÊɾúÌåÎªÔØÌ壬°Ñ´ýÑ¡»ùÒòƬ¶Î¶¨Ïò²åÈëÊɾúÌåÍâ¿Çµ°°×ÖÊ»ùÒòÇø£¬Ê¹ÍâÔ´¶àëÄ»òµ°°×Öʱí´ï²¢Õ¹Ê¾ÓÚÊɾúÌå±íÃæ£¬½ø¶øÍ¨¹ýÇ׺͸»¼¯·¨±í´ïÓÐÌØÒìëÄ»òµ°°×ÖʵÄÊɾúÌå. Æä½¨Á¢»ùÓÚÈý¸öÔ­Òò£º(1)ÔÚp ¢óºÍp ¢øÒ¿ǵ°°×µÄN ¶Ë²åÈëÍâÔ´»ùÒò£¬ÐγɵÄÈںϵ°°×±í´ïÔÚÊɾúÌå¿ÅÁ£µÄ±íÃæ£¬²»Ó°ÏìºÍ¸ÉÈÅÊɾúÌåµÄÉú»îÖÜÆÚ£¬Í¬Ê±±£³ÖµÄÍâÔ´»ùÒòÌìÈ»¹¹Ïó£¬Ò²Äܱ»ÏàÓ¦µÄ¿¹Ìå»òÊÜÌåËùʶ±ð£»(2)ÀûÓù̶¨Óë¹ÌÏàÖ§³ÖÎïµÄ°Ð·Ö×Ó£¬²ÉÓÃÊʵ±µÄÌÔÏ´(panning)·½·¨£¬Ï´È¥·ÇÌØÒì½áºÏµÄÊɾúÌ壬ɸѡ³öÄ¿µÄÊɾúÌ壻(3)ÍâÔ´¶àëÄ»òµ°°×Öʱí´ïÔÚÊɾúÌåµÄ±íÃæ£¬¶øÆä±àÂë»ùÒò×÷Ϊ²¡¶¾»ùÒò×éÖеÄÒ»²¿·Ö¿Éͨ¹ý·ÖÃÚÐÍÊɾúÌåµÄµ¥Á´DNA ²âÐòÍÆµ¼³öÀ´. ¸Ã¼¼ÊõʵÏÖÁË»ùÒòÐͺͱíÐ͵Äת»».

ÊɾúÌå½á¹¹µ°°×p ¢óºÍp ¢ø¾ù¿É×÷ÎªÔØÌåÀ´Õ¹Ê¾ÍâÔ´¶àëÄ»òµ°°×ÖÊ£¬ÔÚ»ùÒò²Ù×÷ÉÏ£¬ËûÃÇ»ù±¾Ïàͬ. ÔÚÐźÅëÄÓë³ÉÊìµ°°×ÖʱàÂëÇøÖ®¼äÓе¥Ò»µÄ¿Ë¡λµã±ãÓÚ²åÈ룬²åÈëµÄÍâÔ´¶àëÄ»òµ°°×ÖÊÒÔÈںϵÄÐÎʽ±í´ï³öÀ´²¢·ÖÃÚµ½°û¼äÖÊÄÚ£¬µ±ËÞÖ÷µ°°×øÇгýÐźÅëĺó£¬Èںϵ°°××é×°³ÉÊ죬³ÊÏÖÔÚ²¡¶¾Á£×ӵıíÃæ£¬ÐµÄN ¶ËλÖÃÕýÊÇÍâÔ´µ°°×»ò¶àëĵIJåÈëµã. Óëp ¢ó»ùÒòÈÚºÏʱ¿½±´ÊýµÍ(²»³¬¹ý5 ¸ö)£¬Õâ¿ÉÒÔ¼õÉÙ¶à¼Û½áºÏ£¬ÀûÓÚÑ¡Ôñ¸ßÇ׺ÍÁ¦µÄÅäÌå·Ö×Ó£¬¿ÉÈÝÐí²åÈë´óµÄƬ¶Î. Óë p ¢ø»ùÒòÈÚºÏʱ£¬¿½±´Êý¸ß(2 700 ¸ö)£¬µ±½«ÊôÓÚ¶àëĵıíλÓÃ×÷ÃâÒßԴʱ¿É²úÉúÁ¼ºÃµÄÃâÒßÓ¦´ð£¬¾ßÓз´Ó¦ÓÅÊÆ£¬¹ÊÔÚÒßÃ翪·¢ÉϾßÓÐDZÔÚµÄÓ¦ÓüÛÖµ.
5Â¥2009-12-01 14:47:27
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ kitty-II µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 290Çóµ÷¼Á +6 ¿×Ö¾ºÆ 2026-03-12 11/550 2026-03-17 14:41 by ÖÜÖÛÖÛ77
[¿¼ÑÐ] ²ÄÁÏÓ뻯¹¤Çóµ÷¼Á +4 Ϊѧ666 2026-03-16 4/200 2026-03-17 14:28 by houyaoxu
[¿¼ÑÐ] ²ÄÁÏר˶306Ó¢Ò»Êý¶þ +6 z1z2z3879 2026-03-16 8/400 2026-03-17 14:03 by Ó¸ÒÌ«¼àÍõ¹«¹«
[¿¼ÑÐ] ²ÄÁÏÓ뻯¹¤×¨Ë¶µ÷¼Á +5 heming3743 2026-03-16 5/250 2026-03-17 14:03 by Ó¸ÒÌ«¼àÍõ¹«¹«
[¿¼ÑÐ] 08¹¤¿Æ 320×Ü·Ö Çóµ÷¼Á +4 À滨çóÍí·ç 2026-03-17 4/200 2026-03-17 13:38 by houyaoxu
[¿¼ÑÐ] 290Çóµ÷¼Á +6 @½«¾Í½«¾Í¿´ 2026-03-10 11/550 2026-03-17 10:22 by @½«¾Í½«¾Í¿´
[¿¼ÑÐ] 11408 Ò»Ö¾Ô¸Î÷µç£¬277·ÖÇóµ÷¼Á +3 zhouzhen654 2026-03-16 3/150 2026-03-17 07:03 by laoshidan
[¿¼ÑÐ] 333Çóµ÷¼Á +3 ÎÄ˼¿Í 2026-03-16 7/350 2026-03-16 18:21 by ÎÄ˼¿Í
[¿¼ÑÐ] 326Çóµ÷¼Á +4 ŵ±´¶û»¯Ñ§½±êéê 2026-03-15 7/350 2026-03-16 17:11 by ŵ±´¶û»¯Ñ§½±êéê
[¿¼ÑÐ] 304Çóµ÷¼Á +4 ahbd 2026-03-14 4/200 2026-03-16 16:48 by ÎҵĴ¬Îҵĺ£
[¿¼ÑÐ] 283Çóµ÷¼Á +10 С¥¡£ 2026-03-12 14/700 2026-03-16 16:08 by 13811244083
[½Ìʦ֮¼Ò] ½¹ÂÇ +7 Ë®±ùÔÂÔÂÒ°Íà 2026-03-13 9/450 2026-03-16 10:00 by Quakerbird
[¿¼²©] ¶«»ªÀí¹¤´óѧ»¯²Äרҵ26½ì˶ʿ²©Ê¿ÉêÇë +6 zlingli 2026-03-13 6/300 2026-03-15 20:00 by ryzcf
[¿¼ÑÐ] 304Çóµ÷¼Á +6 Mochaaaa 2026-03-12 7/350 2026-03-13 22:18 by ÐÇ¿ÕÐÇÔÂ
[¿¼ÑÐ] ²ÄÁÏÓ뻯¹¤Çóµ÷¼ÁÒ»Ö¾Ô¸ 985 ×Ü·Ö 295 +8 dream¡­¡­ 2026-03-12 8/400 2026-03-13 22:17 by ÐÇ¿ÕÐÇÔÂ
[¿¼ÑÐ] Ò»Ö¾Ô¸Î÷ÄϽ»´ó£¬²ÄÁÏר˶317Çóµ÷¼Á +5 lx8568 2026-03-11 5/250 2026-03-13 21:43 by peike
[¿¼ÑÐ] ¡¾¿¼Ñе÷¼ÁÇóÊÕÁô¡¿ +3 Ceciilia 2026-03-11 3/150 2026-03-13 20:18 by JourneyLucky
[¿¼ÑÐ] һ־Ըɽ´ó07»¯Ñ§ 332·Ö ËÄÁù¼¶Òѹý ±¾¿ÆÉ½¶«Ë«·Ç Çóµ÷¼Á£¡ +3 ²»ÏëÀíÄã 2026-03-12 3/150 2026-03-13 14:18 by JourneyLucky
[¿¼ÑÐ] 420Çóµ÷¼Á +4 ĪÏòÍâÇó11 2026-03-10 6/300 2026-03-12 14:41 by ruiyingmiao
[¿¼ÑÐ] ´óÁ¬´óѧ»¯Ñ§×¨ÒµÑо¿Éúµ÷¼Á +3 ç÷¾Ã. 2026-03-10 8/400 2026-03-11 10:02 by ç÷¾Ã.
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û